V12 SENTINEL ENGINE · AI MARKET ANALYSIS
Mid
A
AMGNAI Stock Diagnostic Report

Amgen, Astra post late-stage trial win for asthma drug Tezspire in swallowing disorder

Amgen and AstraZeneca's asthma treatment Tezspire succeeded in a Phase 3 trial for an esophageal inflammatory disease.

View Source Article ↗
AI CATALYST SCORE75 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+
ANALYSIS HISTORY

AMGN Analysis History (Last 30 Days)

Diagnosed AtTickerAI ScoreTier
2026-08-28 12:24:55AMGN75MidView Report →
2026-08-07 23:34:04AMGN30RowView Report →
2026-08-07 23:34:00AMGN35RowView Report →
View Full History for AMGN (Blueprint) →